Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats

Elizabeth Hohnadel, Kristy Bouchard, Alvin V Terry

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Acetylcholinesterase inhibitors (AChEIs) are currently being evaluated as adjunctive therapy for the cognitive dysfunction of schizophrenia. This core symptom of schizophrenia has often been attributed to impaired attention and abnormal sensory motor gating, features that are also found in Huntington's Disease, autism, and several other psychiatric and neurological disorders. The ability to improve prepulse inhibition (PPI) of the acoustic startle response may predict the efficacy of compounds as cognitive enhancers. In this study, PPI was disrupted in Wistar rats in three pharmacologic models: dopamine receptor agonism by apomorphine, NMDA receptor antagonism by MK801, or muscarinic acetylcholine receptor antagonism by scopolamine. We then evaluated the commonly used AChEIs, donepezil (0.5, 1.0, or 2.0 mg/kg) and galantamine (0.3, 1.0, or 3.0 mg/kg) for the capacity to improve PPI in each model. Under vehicle conditions, the prepulse stimuli (75, 80 and 85 dB) inhibited the startle response to a 120 dB auditory stimulus in a graded fashion. Galantamine (depending on dose) improved PPI deficits in all three PPI disruption models, whereas donepezil ameliorated PPI deficits induced by scopolamine and apomorphine, but was not effective in the MK801 model. These results indicate that some AChEIs may have the potential to improve cognition in schizophrenia by improving auditory sensory gating.

Original languageEnglish (US)
Pages (from-to)542-551
Number of pages10
JournalNeuropharmacology
Volume52
Issue number2
DOIs
StatePublished - Feb 1 2007

Fingerprint

Galantamine
Cholinesterase Inhibitors
Startle Reflex
Sensory Gating
Schizophrenia
Scopolamine Hydrobromide
Apomorphine
Nootropic Agents
Aptitude
Huntington Disease
Dopamine Receptors
Muscarinic Receptors
Autistic Disorder
Nervous System Diseases
N-Methyl-D-Aspartate Receptors
Acoustics
Cognition
Psychiatry
donepezil
Prepulse Inhibition

Keywords

  • Acetylcholine
  • Acetylcholinesterase
  • Cholinergic
  • Cognition
  • Memory
  • Schizophrenia

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Drug Discovery
  • Pharmacology

Cite this

Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats. / Hohnadel, Elizabeth; Bouchard, Kristy; Terry, Alvin V.

In: Neuropharmacology, Vol. 52, No. 2, 01.02.2007, p. 542-551.

Research output: Contribution to journalArticle

@article{cc9c297032e14c8b86eb6e33d532f461,
title = "Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats",
abstract = "Acetylcholinesterase inhibitors (AChEIs) are currently being evaluated as adjunctive therapy for the cognitive dysfunction of schizophrenia. This core symptom of schizophrenia has often been attributed to impaired attention and abnormal sensory motor gating, features that are also found in Huntington's Disease, autism, and several other psychiatric and neurological disorders. The ability to improve prepulse inhibition (PPI) of the acoustic startle response may predict the efficacy of compounds as cognitive enhancers. In this study, PPI was disrupted in Wistar rats in three pharmacologic models: dopamine receptor agonism by apomorphine, NMDA receptor antagonism by MK801, or muscarinic acetylcholine receptor antagonism by scopolamine. We then evaluated the commonly used AChEIs, donepezil (0.5, 1.0, or 2.0 mg/kg) and galantamine (0.3, 1.0, or 3.0 mg/kg) for the capacity to improve PPI in each model. Under vehicle conditions, the prepulse stimuli (75, 80 and 85 dB) inhibited the startle response to a 120 dB auditory stimulus in a graded fashion. Galantamine (depending on dose) improved PPI deficits in all three PPI disruption models, whereas donepezil ameliorated PPI deficits induced by scopolamine and apomorphine, but was not effective in the MK801 model. These results indicate that some AChEIs may have the potential to improve cognition in schizophrenia by improving auditory sensory gating.",
keywords = "Acetylcholine, Acetylcholinesterase, Cholinergic, Cognition, Memory, Schizophrenia",
author = "Elizabeth Hohnadel and Kristy Bouchard and Terry, {Alvin V}",
year = "2007",
month = "2",
day = "1",
doi = "10.1016/j.neuropharm.2006.08.025",
language = "English (US)",
volume = "52",
pages = "542--551",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats

AU - Hohnadel, Elizabeth

AU - Bouchard, Kristy

AU - Terry, Alvin V

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Acetylcholinesterase inhibitors (AChEIs) are currently being evaluated as adjunctive therapy for the cognitive dysfunction of schizophrenia. This core symptom of schizophrenia has often been attributed to impaired attention and abnormal sensory motor gating, features that are also found in Huntington's Disease, autism, and several other psychiatric and neurological disorders. The ability to improve prepulse inhibition (PPI) of the acoustic startle response may predict the efficacy of compounds as cognitive enhancers. In this study, PPI was disrupted in Wistar rats in three pharmacologic models: dopamine receptor agonism by apomorphine, NMDA receptor antagonism by MK801, or muscarinic acetylcholine receptor antagonism by scopolamine. We then evaluated the commonly used AChEIs, donepezil (0.5, 1.0, or 2.0 mg/kg) and galantamine (0.3, 1.0, or 3.0 mg/kg) for the capacity to improve PPI in each model. Under vehicle conditions, the prepulse stimuli (75, 80 and 85 dB) inhibited the startle response to a 120 dB auditory stimulus in a graded fashion. Galantamine (depending on dose) improved PPI deficits in all three PPI disruption models, whereas donepezil ameliorated PPI deficits induced by scopolamine and apomorphine, but was not effective in the MK801 model. These results indicate that some AChEIs may have the potential to improve cognition in schizophrenia by improving auditory sensory gating.

AB - Acetylcholinesterase inhibitors (AChEIs) are currently being evaluated as adjunctive therapy for the cognitive dysfunction of schizophrenia. This core symptom of schizophrenia has often been attributed to impaired attention and abnormal sensory motor gating, features that are also found in Huntington's Disease, autism, and several other psychiatric and neurological disorders. The ability to improve prepulse inhibition (PPI) of the acoustic startle response may predict the efficacy of compounds as cognitive enhancers. In this study, PPI was disrupted in Wistar rats in three pharmacologic models: dopamine receptor agonism by apomorphine, NMDA receptor antagonism by MK801, or muscarinic acetylcholine receptor antagonism by scopolamine. We then evaluated the commonly used AChEIs, donepezil (0.5, 1.0, or 2.0 mg/kg) and galantamine (0.3, 1.0, or 3.0 mg/kg) for the capacity to improve PPI in each model. Under vehicle conditions, the prepulse stimuli (75, 80 and 85 dB) inhibited the startle response to a 120 dB auditory stimulus in a graded fashion. Galantamine (depending on dose) improved PPI deficits in all three PPI disruption models, whereas donepezil ameliorated PPI deficits induced by scopolamine and apomorphine, but was not effective in the MK801 model. These results indicate that some AChEIs may have the potential to improve cognition in schizophrenia by improving auditory sensory gating.

KW - Acetylcholine

KW - Acetylcholinesterase

KW - Cholinergic

KW - Cognition

KW - Memory

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=33846313139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846313139&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2006.08.025

DO - 10.1016/j.neuropharm.2006.08.025

M3 - Article

C2 - 17046031

AN - SCOPUS:33846313139

VL - 52

SP - 542

EP - 551

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 2

ER -